Experimental Medication Shows Promising Results in Treating Advanced Cancers
A recent clinical study has demonstrated the efficacy of an experimental medication, Setidegrasib, in treating certain advanced cancers. The study, published in the prestigious medical journal The New England Journal of Medicine, highlights the medication's ability to slow tumor progression and reduce tumor size in a subset of patients.
The study focused on advanced cases of lung cancer and pancreatic cancer, two particularly challenging conditions to treat, especially in the absence of effective therapeutic options at an advanced stage. The medication targets a specific genetic mutation, KRAS G12D, known to play a crucial role in the development and survival of cancer cells. This mutation affects approximately 40% of pancreatic cancers and nearly 5% of non-small cell lung cancers, but has long been difficult to target.
Unlike traditional approaches that involve blocking cancer-causing proteins, Setidegrasib works by directly destroying these proteins within tumor cells, a strategy that could potentially improve its efficacy.
The first phase of clinical trials involved 203 patients, distributed across 28 centers in five countries, all of whom had previously received treatments without satisfactory results. Researchers identified an optimal dose of 600 mg administered intravenously once a week.
The results show that 36% of patients with lung cancer who received this dose observed a reduction in tumor size, with a median response duration of 8.3 months. In patients with pancreatic cancer, 24% experienced improvement, with a median survival of 10.3 months for those who had already undergone heavy treatment.
Biological analyses also confirmed a decrease in the levels of the targeted protein in tumors, as well as a reduction in tumor markers in the blood.
Well-Tolerated Treatment with Minimal Side Effects
The treatment was generally well-tolerated, with side effects such as skin rashes, itching, and nausea being mostly mild to moderate and controllable with medical treatment.
According to Jonathan Goldman, one of the study's lead authors, these results, although preliminary, are significant: "We're working with cancers for which targeted therapeutic options have been limited until now."
He believes that if these results are confirmed, they could pave the way for a new therapeutic approach that aims not only to block cancer-causing proteins but to eliminate them completely.
Additional trials are underway to compare this treatment with existing therapies and expand this strategy to other types of cancer.
